Page last updated: 2024-11-06

n,n-bis(trimethylsilyl)-2,2,2-trifluoroacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

n,n-bis(trimethylsilyl)-2,2,2-trifluoroacetamide, also known as BSTFA, is a widely used reagent in analytical chemistry for the derivatization of compounds containing hydroxyl, carboxyl, or amino groups. It is employed to enhance volatility and stability of analytes, making them suitable for gas chromatography-mass spectrometry (GC-MS) analysis. BSTFA reacts with these functional groups to form trimethylsilyl (TMS) derivatives, which are more volatile and less polar than the original compounds. The reaction is typically catalyzed by a base, such as triethylamine or imidazole. BSTFA is particularly valuable in the analysis of polar compounds, such as carbohydrates, steroids, and amino acids, which are often difficult to analyze directly by GC-MS. Its use allows for sensitive and accurate quantification of these compounds in various matrices, including biological samples, environmental samples, and food products.'

Cross-References

ID SourceID
PubMed CID65279
SCHEMBL ID50594
MeSH IDM0136615

Synonyms (28)

Synonym
acetamide, 2,2,2-trifluoro-n,n-bis(trimethylsilyl)-
2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide
21149-38-2
trimethylsilyl n-trimethylsilyltrifluoroacetimidate
unii-5t8na426kz
5t8na426kz ,
n,n-bis(trimethylsilyl)-2,2,2-trifluoroacetamide
einecs 244-242-7
FT-0629599
AKOS015901231
n,n-bis(trimethylsilyl)trifluoroacetamide
SCHEMBL50594
DTXSID8066682
bistrimethylsilyltrifluoroacetamide
bistrimethylsilyl-trifluoroacetamide
bistrimethylsilyltrifluoro- acetamide
bis-(trimethylsilyl) trifluoroacetamide
bis (trimethylsilyl)trifluoroacetamide
bis(trimethylsilyl) trifluoroacetamide
bis-(trimethylsilyl)trifluoroacetamide
bis-trimethylsilyltrifluoroacetamide
trifluoroacetamide, 2tms derivative
2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide #
n,n-bstfa
AMY3626
F50694
Q27262838
trifluoroacetyl(bis(trimethylsilyl))amine

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In order to examine their bioavailability in humans, we have developed and validated a sensitive method to quantify icaritin and desmethylicaritin in human sera, using gas chromatography-mass spectrometry."( Sensitive and rapid method to quantify icaritin and desmethylicaritin in human serum using gas chromatography-mass spectrometry.
Shen, P; Wong, SP; Yong, EL, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
"Two potential anti-asthmatic alpha-methylacetohydroxamic acids, compound 1 and compound II were metabolised to two major products (metabolite 1 and metabolite 2) after oral dosing to rabbits."( Use of high-performance liquid chromatography-thermospray mass spectrometry and gas chromatography-electron-impact mass spectrometry in the identification of the metabolites of alpha-methylacetohydroxamic acids, potential anti-asthmatic agents.
Padfield, AD; Salmon, JA; Woollard, PM, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.00)18.7374
1990's15 (20.00)18.2507
2000's28 (37.33)29.6817
2010's28 (37.33)24.3611
2020's1 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.81 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other74 (98.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]